Fetal microchimerism and cancer

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 8-13

  Gadi, Vijayakrishna K ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast cancer; Microchimerism; Tumor immunology

Indexed keywords

ALLOIMMUNITY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER IMMUNOLOGY; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; FETAL MICROCHIMERISM; FETUS CELL; FETUS DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; MICROCHIMERISM; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; SHORT SURVEY; THYROID ADENOMA; THYROID CARCINOMA; UTERINE CERVIX CANCER;

EID: 60249099032     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.025     Document Type: Review

References (74)

1. Hortobagyi G.N., de la Garza Salazar J., Pritchard K., Amadori D., Haidinger R., Hudis C.A., Khaled H., Liu M.C., Martin M., Namer M., O'Shaughnessy J.A., Shen Z.Z., and Albain K.S. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer 6 (2005) 391-401
2. Ganz P.A. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am. J. Med. 118 (2005) 136-141
3. Chen S., Iversen E.S., Friebel T., Finkelstein D., Weber B.L., Eisen A., Peterson L.E., Schildkraut J.M., Isaacs C., Peshkin B.N., Corio C., Leondaridis L., Tomlinson G., Dutson D., Kerber R., Amos C.I., Strong L.C., Berry D.A., Euhus D.M., and Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J. Clin. Oncol. 24 (2006) 863-871
4. McClain M.R., Palomaki G.E., Nathanson K.L., and Haddow J.E. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med. 7 (2005) 28-33
5. Glaser S.L., Clarke C.A., Nugent R.A., Stearns C.B., and Dorfman R.F. Reproductive factors in Hodgkin's disease in women. Am. J. Epidemiol. 158 (2003) 553-563
6. Zhang Y., Holford T.R., Leaderer B., Boyle P., Zahm S.H., Zhang B., Zou K., Morton L.M., Owens P.H., Flynn S., Tallini G., and Zheng T. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. Am. J. Epidemiol. 160 (2004) 766-773
7. Ekstrom K., Wuu J., Hsieh C.C., Glimelius B., and Lambe M. Childbearing and the risk of leukemia in Sweden. Cancer Causes Control 13 (2002) 47-53
8. Adami H.O., Tsaih S., Lambe M., Hsieh C., Adami J., Trichopoulos D., Melbye M., and Glimelius B. Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study. Int. J. Cancer 70 (1997) 155-158
9. Cantor K.P., Lynch C.F., and Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 3 (1992) 57-62
10. Nichols H.B., Trentham-Dietz A., Hampton J.M., and Newcomb P.A. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1212-1218
11. Riman T., Nilsson S., and Persson I.R. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol. Scand. 83 (2004) 783-795
12. Skinner H.G., Michaud D.S., Colditz G.A., Giovannucci E.L., Stampfer M.J., Willett W.C., and Fuchs C.S. Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 433-438
13. Hatch E.E., Linet M.S., Zhang J., Fine H.A., Shapiro W.R., Selker R.G., Black P.M., and Inskip P.D. Reproductive and hormonal factors and risk of brain tumors in adult females. Int. J. Cancer 114 (2005) 797-805
14. Lambe M., Hsieh C.C., Chan H.W., Ekbom A., Trichopoulos D., and Adami H.O. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res. Treat. 38 (1996) 305-311
15. Layde P.M., Webster L.A., Baughman A.L., Wingo P.A., Rubin G.L., and Ory H.W. The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group. J. Clin. Epidemiol. 42 (1989) 963-973
16. Antoniou A.C., Shenton A., Maher E.R., Watson E., Woodward E., Lalloo F., Easton D.F., and Evans D.G. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 8 (2006) R72
17. Velie E.M., Nechuta S., and Osuch J.R. Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis. 24 (2005) 17-35
18. Pike M.C., Pearce C.L., and Wu A.H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23 (2004) 6379-6391
19. Russo J., Balogh G.A., Heulings R., Mailo D.A., Moral R., Russo P.A., Sheriff F., Vanegas J., and Russo I.H. Molecular basis of pregnancy-induced breast cancer protection. Eur. J. Cancer Prev. 15 (2006) 306-342
20. Gubersky M., Thomson D.M., and Lajzerowicz M. Expression by human fetal organs of organ-specific cancer neoantigens as measured by leukocyte adherence inhibition. Cancer Immunol. Immunother. 21 (1986) 107-113
21. Higuchi M., Robinson D.S., Cailleau R., Irie R.F., and Morton D.L. A serologic study of cultured breast cancer cell lines: lack of antibody response to tumour specific membrane antigens in patients. Clin. Exp. Immunol. 39 (1980) 90-96
22. Janerich D.T. The fetal antigen hypothesis for breast cancer, revisited. Med. Hypotheses 43 (1994) 105-110
23. Reinerova M.H., Rosen H.R., Veselovska Z., Stierer M., and Svec J. Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D. Neoplasma 40 (1993) 147-151
24. Rasmussen H.B., Teisner B., Andersen J.A., Yde-Andersen E., Skjodt K., and Schroder H.D. Foetal antigen 2 (FA2) in the stromal reaction induced by breast carcinoma. Apmis 100 (1992) 39-47
25. Rohrer J.W., Barsoum A.L., Dyess D.L., Tucker J.A., and Coggin Jr. J.H. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J. Immunol. 162 (1999) 6880-6892
26. Herzenberg L.A., Bianchi D.W., Schroder J., Cann H.M., and Iverson G.M. Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-activated cell sorting. Proc. Natl. Acad. Sci. USA 76 (1979) 1453-1455
27. Lo Y.M., Patel P., Sampietro M., Gillmer M.D., Fleming K.A., and Wainscoat J.S. Detection of single-copy fetal DNA sequence from maternal blood. Lancet 335 (1990) 1463-1464
28. Lo Y.M., Patel P., Wainscoat J.S., Sampietro M., Gillmer M.D., and Fleming K.A. Prenatal sex determination by DNA amplification from maternal peripheral blood. Lancet 2 (1989) 1363-1365
29. Bianchi D.W., Zickwolf G.K., Weil G.J., Sylvester S., and DeMaria M.A. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl. Acad. Sci. USA 93 (1996) 705-708
30. Evans P.C., Lambert N., Maloney S., Furst D.E., Moore J.M., and Nelson J.L. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 93 (1999) 2033-2037
31. Lambert N.C., Lo Y.M., Erickson T.D., Tylee T.S., Guthrie K.A., Furst D.E., and Nelson J.L. Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. Blood 100 (2002) 2845-2851
32. Zhong X.Y., Holzgreve W., and Hahn S. Direct quantification of fetal cells in maternal blood by real-time PCR. Prenat. Diagn. 26 (2006) 850-854
33. Bianchi D.W., Williams J.M., Sullivan L.M., Hanson F.W., Klinger K.W., and Shuber A.P. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am. J. Hum. Genet. 61 (1997) 822-829
34. Loubiere L.S., Lambert N.C., Flinn L.J., Erickson T.D., Yan Z., Guthrie K.A., Vickers K.T., and Nelson J.L. Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells. Lab. Invest. (2006)
35. Khosrotehrani K., Johnson K.L., Cha D.H., Salomon R.N., and Bianchi D.W. Transfer of fetal cells with multilineage potential to maternal tissue. Jama 292 (2004) 75-80
36. Khosrotehrani K., and Bianchi D.W. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J. Cell. Sci. 118 (2005) 1559-1563
37. Stevens A.M., McDonnell W.M., Mullarkey M.E., Pang J.M., Leisenring W., and Nelson J.L. Liver biopsies from human females contain male hepatocytes in the absence of transplantation. Lab. Invest. 84 (2004) 1603-1609
38. Adams K.M., Lambert N.C., Heimfeld S., Tylee T.S., Pang J.M., Erickson T.D., and Nelson J.L. Male DNA in female donor apheresis and CD34-enriched products. Blood 102 (2003) 3845-3857
39. O'Donoghue K., Chan J., de la Fuente J., Kennea N., Sandison A., Anderson J.R., Roberts I.A., and Fisk N.M. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet 364 (2004) 179-182
40. Scaletti C., Vultaggio A., Bonifacio S., Emmi L., Torricelli F., Maggi E., Romagnani S., and Piccinni M.P. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum. 46 (2002) 445-450
41. Esposito C., Cornacchia F., Roberta Riboni R., Gianluca Fasoli G., Parrilla B., Scudellaro R., Villa L., Mangione F., Serpieri N., and Canton A.D. Feto-maternal microchimerism in glomerular cells: a possible role in lupus nephritis. Nephrol. Dial. Transplant. 20 (2005) v197
42. Bayes-Genis A., Bellosillo B., de la Calle O., Salido M., Roura S., Ristol F.S., Soler C., Martinez M., Espinet B., Serrano S., Bayes de Luna A., and Cinca J. Identification of male cardiomyocytes of extracardiac origin in the hearts of women with male progeny: male fetal cell microchimerism of the heart. J. Heart Lung Transplant. 24 (2005) 2179-2183
43. Khosrotehrani K., Reyes R.R., Johnson K.L., Freeman R.B., Salomon R.N., Peter I., Stroh H., Guegan S., and Bianchi D.W. Fetal cells participate over time in the response to specific types of murine maternal hepatic injury. Hum. Reprod. 22 (2007) 654-661
44. Lo Y.M., Hjelm N.M., Fidler C., Sargent I.L., Murphy M.F., Chamberlain P.F., Poon P.M., Redman C.W., and Wainscoat J.S. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N. Engl. J. Med. 339 (1998) 1734-1738
45. Lo Y.M., Lau T.K., Chan L.Y., Leung T.N., and Chang A.M. Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin. Chem. 46 (2000) 1301-1309
46. Lambert N.C., Erickson T.D., Yan Z., Pang J.M., Guthrie K.A., Furst D.E., and Nelson J.L. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. Arthritis Rheum. 50 (2004) 906-914
47. Gadi V.K., and Nelson J.L. Fetal microchimerism in women with breast cancer. Cancer Res. 67 (2007) 9035-9038
48. Gadi V.K., Malone K.E., Guthrie K.A., Porter P.L., and Nelson J.L. Case-control study of fetal microchimerism and breast cancer. PLoS ONE 3 (2008) e1706
49. Dubernard G., Aractingi S., Oster M., Rouzier R., Mathieu M.C., Uzan S., and Khosrotehrani K. Breast cancer stroma frequently recruits fetal derived cells during pregnancy. Breast Cancer Res. 10 (2008) R14
50. Cha D., Khosrotehrani K., Kim Y., Stroh H., Bianchi D.W., and Johnson K.L. Cervical cancer and microchimerism. Obstet Gynecol. 102 (2003) 774-781
51. Srivatsa B., Srivatsa S., Johnson K.L., Samura O., Lee S.L., and Bianchi D.W. Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study. Lancet 358 (2001) 2034-2038
52. Renne C., Ramos Lopez E., Steimle-Grauer S.A., Ziolkowski P., Pani M.A., Luther C., Holzer K., Encke A., Wahl R.A., Bechstein W.O., Usadel K.H., Hansmann M.L., and Badenhoop K. Thyroid fetal male microchimerisms in mothers with thyroid disorders: presence of Y-chromosomal immunofluorescence in thyroid-infiltrating lymphocytes is more prevalent in Hashimoto's thyroiditis and Graves' disease than in follicular adenomas. J. Clin. Endocrinol. Metab. 89 (2004) 5810-5814
53. Maloney S., Smith A., Furst D.E., Myerson D., Rupert K., Evans P.C., and Nelson J.L. Microchimerism of maternal origin persists into adult life. J. Clin. Invest. 104 (1999) 41-47
54. Jonsson V., Tjonnfjord G., Samuelsen S.O., Johannesen T., Olsen J., Sellick G., Houlston R., Yuille M., and Catovsky D. Birth order pattern in the inheritance of chronic lymphocytic leukaemia and related lymphoproliferative disease. Leuk. Lymphoma 48 (2007) 2387-2396
55. Potter J.F., and Schoeneman M. Metastasis of maternal cancer to the placenta and fetus. Cancer 25 (1970) 380-388
56. Potter J.F. Metastasis of maternal cancer to placenta and fetus. Am. J. Obstet. Gynecol. 105 (1969) 645
57. Brodsky I., Baren M., Kahn S.B., Lewis Jr. G., and Tellem M. Metastatic malignant melanoma from mother to fetus. Cancer 18 (1965) 1048-1054
58. Holland E. A case of transplacental metastasis of malignant melanoma from mother to foetus. J. Obstet. Gynaecol. Br. Emp. 56 (1949) 529-536
59. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., and Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304 (1981) 1529-1533
60. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., and Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300 (1979) 1068-1073
61. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
62. van der Harst D., Goulmy E., Falkenburg J.H., Kooij-Winkelaar Y.M., van Luxemburg-Heijs S.A., Goselink H.M., and Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83 (1994) 1060-1066
63. Marijt W.A., Veenhof W.F., Goulmy E., Willemze R., van Rood J.J., and Falkenburg J.H. Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood 82 (1993) 3778-3785
64. Ho V.T., Kim H.T., Liney D., Milford E., Gribben J., Cutler C., Lee S.J., Antin J.H., Soiffer R.J., and Alyea E.P. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 37 (2006) 845-850
65. Shaw B.E., Marsh S.G., Mayor N.P., Russell N.H., and Madrigal J.A. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 107 (2006) 1220-1226
66. Petersdorf E.W. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract. Res. Clin. Haematol. 20 (2007) 155-170
67. Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W., Otterud B.E., Leppert M.F., Storb R., and Sandmaier B.M. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10 (2004) 7799-7811
68. Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., Read E.J., Tisdale J., Dunbar C., Linehan W.M., Young N.S., and Barrett A.J. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343 (2000) 750-758
69. Bishop M.R., Fowler D.H., Marchigiani D., Castro K., Kasten-Sportes C., Steinberg S.M., Gea-Banacloche J.C., Dean R., Chow C.K., Carter C., Read E.J., Leitman S., and Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. 22 (2004) 3886-3892
70. Bregni M., Dodero A., Peccatori J., Pescarollo A., Bernardi M., Sassi I., Voena C., Zaniboni A., Bordignon C., and Corradini P. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99 (2002) 4234-4236
71. Or R., Ackerstein A., Nagler A., Kapelushnik J., Naparstek E., Samuel S., Amar A., Bruatbar C., and Slavin S. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol. Ther. 4 (1998) 1-6
72. Ueno N.T., Cheng Y.C., Rondon G., Tannir N.M., Gajewski J.L., Couriel D.R., Hosing C., de Lima M.J., Anderlini P., Khouri I.F., Booser D.J., Hortobagyi G.N., Pagliaro L.C., Jonasch E., Giralt S.A., and Champlin R.E. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102 (2003) 3829-3836
73. van Rood J.J., and Claas F. Both self and non-inherited maternal HLA antigens influence the immune response. Immunol. Today 21 (2000) 269-273
74. Ichinohe T., Uchiyama T., Shimazaki C., Matsuo K., Tamaki S., Hino M., Watanabe A., Hamaguchi M., Adachi S., Gondo H., Uoshima N., Yoshihara T., Hatanaka K., Fujii H., Kawa K., Kawanishi K., Oka K., Kimura H., Itoh M., Inukai T., Maruya E., Saji H., and Kodera Y. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104 (2004) 3821-3828